Semaglutide's Weight Loss Effects in Obesity

Launched by BEIJING CHAO YANG HOSPITAL · Feb 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called semaglutide on weight loss in people who are obese. The goal is to understand how individual differences in gut bacteria, which are tiny organisms in our digestive system, can affect how well people lose weight when using this medication. This trial is currently not recruiting participants but is looking to include adults aged 18 to 60 who have a body mass index (BMI) of 30 or higher and have tried to lose weight through lifestyle changes without success.

To be eligible, participants should not have lost a significant amount of weight recently or used certain medications for weight loss or diabetes in the past three months. They also need to have no serious health issues, such as liver or kidney problems, or a history of certain diseases. If you join the trial, you can expect to learn more about your health and how semaglutide might help with weight loss. Overall, this trial aims to find out more about the connection between gut health and weight loss success, which could lead to better treatments for obesity in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-60 years
• • BMI ≥ 30 kg/m²
• • At least one self-reported unsuccessful attempt at lifestyle weight loss
• Exclusion Criteria:
• • Weight change (self-reported) \> 5% in the past 3 months prior to screening
• • Use of any medication for obesity indication in the past 3 months prior to screening.
• • Use of antidiabetic medications in the past 3 months, or HbA1c ≥ 6.5%, or a history of Type 1 or Type 2 diabetes.
• • Use of immunosuppressants, corticosteroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering medications, and/or other gastrointestinal motility drugs in the past 3 months prior to screening.
• • A history of endocrine-related overweight or obesity diagnoses, such as Cushing's syndrome.
• • Triglycerides ≥ 500 mg/dL (5.65 mmol/L) at screening.
• • Known clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), gastrointestinal diseases, or surgical history.
• • Thyroid dysfunction.
• • History of mental illness.
• • History or family history of multiple endocrine neoplasia or medullary thyroid cancer, or calcitonin ≥ 6 pg/mL.
• • Abnormal liver function at screening, defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 3\*ULN.
• • Abnormal kidney function at screening, defined as estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.75m².
• • History of cardiovascular disease.
• • History of malignancy.
• • Pregnancy or breastfeeding.
• • Any other physiological, psychological, or other conditions deemed by the investigator as unsuitable for participation in the trial.